Active-ingredient Dossier
Dasatinib
Active-ingredient Dossier for Dasatinib (tyrosine kinase inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: DASATINIB-TEVA
- Brand: SPRYCEL
- Brand: DASATINIB
- Brand: DASATINIB
- Brand: DASATINIB DR.REDDY'S
- Brand: DASATINIB SANDOZ
- Therapeutic area: Oncology
What is
Dasatinib Dasatinib is a tyrosine kinase inhibitor.
Australian brands containing
Dasatinib — DASATINIB-TEVA — DASATINIB — SPRYCEL — DASATINIB SANDOZ — DASATINIB VIATRIS — TE-DASATINIB — DASATINIB-DWRN
Therapeutic areas
Dasatinib is registered in oncology, with 10 brands containing the ingredient on the ARTG.
Sponsor landscape
Seven sponsors market dasatinib in Australia: Arrotex Pharmaceuticals, Teva Pharma, Sun Pharma, Sandoz, Helix Pharmaceuticals and Accelagen.
PBS and regulatory activity
One brand containing dasatinib has PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2016–17 financial year, dasatinib generated government expenditure of approximately $44.2 million across 9,096 prescriptions. The latest PBAC outcome is dated 1 May 2023, and the latest AusPAR is dated 7 March 2018.